HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Supplemental Table All Versions of this Article: 32/1/64    most recent 00151.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Mansergh, F. C. Articles by Evans, B. A. J. Search for Related Content PubMed PubMed Citation Articles by Mansergh, F. C. Articles by Evans, B. A. J.

Osteopenia in Sparc (osteonectin)-deficient mice: characterization of phenotypic determinants of femoral strength and changes in gene expression

¹ School of Biosciences, Cardiff University, Cardiff
² Department of Child Health, Cardiff University, Cardiff
³ School of Engineering, Cardiff University, Cardiff
⁴ Department of Anatomy, University of Bristol, Bristol, United Kingdom

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
Sparc null mutants have been generated independently via targeted mutations in exons 4 and 6. Previous studies have identified low-turnover osteopenia in the 129Sv/C57BL/6 exon 4 knockout. Since both Sparc null mutations result in complete absence of Sparc protein, similar phenotypic outcomes are likely. However, genetic background (strain) and/or linkage disequilibrium effects can influence phenotype. Different inactivating mutations should be tested in various mouse strains; similar phenotypic outcomes can then confidently be assigned to the mutated gene. We have evaluated the bone phenotype in the 129Sv/EvSparc^tm1cam exon 6 knockout at 4 and 9 mo, using physical measurement, mechanical strength tests, and DXA scanning. We have also quantified bone marrow adiposity and circulating leptin levels to assess adipose tissue metabolism. 129Sv/EvSparc^tm1cam null mice show decreased bone mineral density and bone mineral content and increased mechanical fragility of bone, in line with previous studies. Differences were also noted. Increased body weight and levels of bone marrow adiposity but decreased circulating leptin concentrations were identified at 4, but not 9 mo, and 129Sv/EvSparc^tm1cam null mice also had shorter femurs. Molecular phenotyping was carried out using mouse HGMP NIA microarrays with cortical femur samples at various ages, using semiquantitative RT-PCR validation. We identified 429 genes highly expressed in normal bone. Six genes (Sparc, Zfp162, Bysl, E2F4, two ESTs) are differentially regulated in 129Sv/EvSparc^tm1cam cortical femur vs. 129Sv/Ev controls. We confirm low-turnover osteopenia as a feature of the Sparc null phenotype, identifying the usefulness of this mouse as a model for human osteoporosis.

osteoporosis; knockout mice; microarray; adiposity

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
TOTAL BONE MASS VARIES throughout life and is regulated via relative rates of bone resorption and deposition. Osteoblasts deposit bone (and are responsible for its developmental formation), while osteoclasts resorb bone, resulting in the constant remodeling of skeletal homeostasis. Osteoblasts are derived from mesenchymal cell populations (20), while osteoclasts are formed via fusion of cells of the monocyte/macrophage family (37); precursors of both are present in the adult bone marrow (27). Osteoporosis is a disorder of skeletal turnover; bone is resorbed faster than it is reformed as a result of imbalances in the activity, or relative numbers of, osteoblasts and osteoclasts (37). Risk factors include sex, hormonal status, race, nutritional status, inadequate resorption/retention of calcium via the digestive system and kidney, lack of weight bearing exercise and low peak bone mass in youth.

Human and animal linkage studies have identified multiple genetic loci that influence bone mass [which is highly variable in humans and between different inbred mouse strains (1, 4, 17, 24, 32)]. Polymorphisms in the COL1A1, TGFβ1, SOST, VDR, ER, LRP5, BMP2, and IL-6 genes, among others, have been implicated in increased osteoporosis risk (17, 21, 32). Moreover, genetically defined mouse mutants have been of particular utility in identifying underlying causes of bone thinning in humans. Gain of function p53 mutants, PASG hypomorphs, PolgA knock-in mutants, and knockouts of BGN, SHIP, OPG, c-Abl, Irs1, klotho, Ku86, XPD, and Sparc all show reductions in bone density (15, 30, 35, 38).

Sparc (a.k.a. osteonectin or BM40) is a calcium, hydroxyapatite and collagen binding protein, implicated in cell proliferation, tissue morphogenesis, and repair and the modeling of extracellular matrix (9). It is widely expressed in development and is present at high levels in bone, possibly linking organic and mineral phases of bone tissue (27). Two independent Sparc knockout lines have been generated. One, Sparc^tm1cam, was generated on both a purebred 129Sv/Ev and a mixed 129Sv/Ev/Mf1^bb background, with an inactivating mutation in exon 6 of the Sparc gene (19). The other knockout (not specifically named but referred to as the Sparc exon 4 knockout) was generated on a 129Sv/C57BL/6 background with an inactivating mutation in exon 4 (2). Both Sparc null mutations have been shown to result in complete absence of Sparc protein via Western blot. Furthermore, testing of a wide variety of tissues and cell lines identified no splice variants of Sparc in mouse (29). Therefore, similar phenotypic outcomes would be likely. Initial analyses revealed subcortical posterior cataract in both lines (2, 19); differences in the timing of cataract onset is most probably genetic background dependent (28). Progressive low-turnover osteopenia has been identified in the 129Sv/C57BL/6 Sparc exon 4 knockout (5, 6, 7, 15, 16). The numbers of osteoblasts and osteoclasts have been shown to be reduced, resulting in a decrease in the rate of bone formation which exceeds the reduction in bone resorption (15). Increased mineral content, crystallinity and collagen maturity were noted, consistent with decreased bone formation and remodeling (5). These Sparc^–/– mice attain a lower peak bone mass with progressive bone loss thereafter (15). Elevated serum leptin concentrations with advancing age, and excessive fat deposits have also been reported; marrow stroma from exon 4 Sparc^–/– mice contained fewer osteoblasts and showed an increased tendency to form adipocytes (30, 35, 38). Interestingly, others have reported that Sparc seems to play a role in adipose tissue physiology (11), and Sparc expression is also altered in at least some forms of human obesity (23).

Genetic background would, however, be expected to influence this phenotype; C57BL/6 mice have comparatively low bone density, while that of 129 strains is typically high (3, 4). We have now studied the bone phenotype in purebred 129Sv/Ev Sparc^tm1cam null mice. Given data suggesting increased adiposity at the expense of bone formation, we have also assessed body weight, bone marrow adipocyte size and number, and circulating leptin concentrations. Measurements of femoral size, strength, and mineral content have confirmed that loss of Sparc causes an osteopenic phenotype, regardless of the nature of the null mutation or the genetic background of the mice. Some differences have been noted between the two Sparc knockout lines, namely differences in femoral length and leptin metabolism not found in previous work with the exon 4 Sparc knockout animals.

We have also used our purebred mice with matched controls to carry out microarray analysis to assess consequent changes in femoral gene expression in ageing Sparc null mice. Six genes, including Sparc, are downregulated in 129SvEv Sparc^tm1cam null mice; we have also used data from controls to identify 429 expressed sequence tags (ESTs) that are highly expressed in normal bone. These may be of importance to the etiology of bone loss during ageing, and also provide a valuable resource for identifying candidate genes for association or linkage studies.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
Mouse nomenclature and strain choice.
129SvEv Sparc^tm1cam null mice: 129SvEv refers to mice of inbred strain 129 and substrain SvEv. Sparc^tm1cam refers to "Sparc, targeted mutation 1, University of Cambridge." This targeted mutation is in exon 6. (The exon 4 knockout has not been similarly named and is referred to here as the exon 4 knockout). Mice used in this study were derived either from mutant homozygote lines or from 129Sv/Ev controls. Male mice were used to minimize the effect of hormonal variation on gene expression levels. For all measurements, experimental and control male animals were killed at 17 and 40 wk time points (4 and 9 mo). Sample sizes of at least six controls and six knockouts were used for each assay. Our inbred mice have been inbred for generations prior to the introduction of the Sparc^tm1cam mutation; moreover, the ES cell lines used to generate this line were themselves of 129SvEv origin. There should therefore be no genetic variation between control and experimental lines other than the Sparc^tm1cam mutation. This should eliminate the possibility of error arising from linkage disequilibrium or from genetic drift between control and experimental lines derived from a mixed background. Elimination of such sources of error is particularly important when assessing results from microarray analyses.

Animal husbandry and tissue extraction.
Mice were maintained and killed under Home Office license in accordance with British law (comparable with US Public Health Service Policy on Humane Care and Use of Laboratory Animals). Transgenic and control animals were maintained on RM3 diet (1.15% calcium, 0.82% phosphorus, 4,088.65 IU/kg vitamin D; Special Diet Services, Witham, Essex, UK) ad libitum. Most animals (except for those used in leptin assays) were killed via cervical dislocation. Whole femurs and tibias were dissected free of surrounding tissue. Bones intended for measurement and/or structural assay were wrapped in sterile PBS-soaked gauze and frozen at –20°C prior to assessment. Tibiae to be sectioned prior to adipocyte counting were placed in 4% paraformaldehyde (PFA). Trunk blood samples for the determination of circulating leptin levels were obtained from halothane-anaesthetized mice via decapitation.

Leptin assay.
Blood samples were collected in heparinized tubes and separated plasma was stored at –20°C prior to determination of plasma leptin concentrations via radioimmunoassay (Linco Research, St. Charles, MO). Intra-assay coefficient of variation (CV) was 4.3%.

Bone marrow adipocyte counting.
Tibiae were fixed in 4% PFA for 2 days after dissection. The PFA was then replaced with a 10% EDTA solution (in 0.3 M NaOH). This solution was refreshed every second day for 3 wk. Following decalcification, the final EDTA wash was replaced with 70% ethanol. Bones were then embedded in paraffin wax, sectioned, and stained with toluidine blue. Sections were visualized using a Leica DMLB microscope and photographed with a Leica DFC300FX camera. Image analysis was carried out using Scion Image. Longitudinal sections of middiaphyseal marrow were assessed for adipocytes following the method previously described by Gevers et al. (18). The total area counted was measured, along with adipocyte number, the area of each adipocyte, total adipocyte area and % of the field occupied by adipocytes. Three sections were counted per animal; sections from six animals were assessed for each of the following four sample types: 4-mo male 129SvEv, 4-mo male 129SvEv Sparc^tm1cam, 9-mo male 129SvEv, 9-mo male 129SvEv Sparc^tm1cam. Statistical analysis of results was carried out using GraphPad Prism v. 2.0.

Femoral length, strength, and morphology.
Previously frozen femurs were thawed at room temperature, and the lengths were measured with a hand-held micrometer. Each bone was then loaded in three-point bending between 2.5-mm-diameter rollers (6.5 mm apart), with the middle roller 3.25 mm from the outer rollers and positioned over the thinnest part of the femoral shaft, level with the distal end of the lateral ridge that runs along the proximal part of the femur toward the greater trochanter. The posterior aspect of the condyles rested on the side of the outer roller, and the bones were orientated such that they were loaded in a roughly posterior direction. Each bone was loaded at a crosshead speed of 2 mm/min until failure, with load and displacement data recorded by the computer controlled testing machine (Lloyd LRX tensile testing machine with 100N load cell; Lloyd Instruments, Segensworth, Hants, UK). Middiaphyseal cortical medio-lateral and anterior posterior diameters, and lateral, medial, anterior, and posterior wall thicknesses were measured at the fracture site using a Pye traveling microscope. Using these measurements and simple beam theory, ultimate tensile stress (UTS) was calculated using: = My/I, where the bending moment, M, is one-half the applied load multiplied by the distance from the central support, y is one-half the outside depth, and the second moment of area, I, is given by:

where b and d are the breadth and depth of the cross-section, respectively, and the subscripts o and i indicate the outside and inside dimensions, respectively.

Femoral mineralization.
Bone mineral content (BMC) was measured by dual-energy X-ray absorptiometry using the Lunar Pixi small animal scanner. The accuracy of this technique in measuring calcium content was confirmed in preliminary studies, in which a highly significant correlation between femoral total BMC and ash weight (r = 0.86; P < 0.0001) was obtained (34). The CV for femoral bone mineral density (BMD) for five repeated scans of 30 femurs, with repositioning between scans, was 2.7%. Bones were thawed at room temperature for 30 min before measurement and aligned anterior-posteriorly relative to the scanning beam. Measurements of total BMC (g) and scanned bone area (BA; cm²) were made, and areal BMD (aBMD; g/cm²) was calculated as BMC/BA. In addition distal femur aBMD were determined by measuring BMC in a fixed area (0.03 cm²) of each region of interest.

Statistical analysis.
All data are presented as means ± SD. The differences between two experimental groups were compared by the unpaired Student t-test (*, **, and *** P < 0.05, 0.01 and 0.001, respectively, vs. control of the same age; +, ++, and +++ P < 0.05, 0.01, and 0.001, respectively, vs. same animal at different age).

RNA extraction for array analysis.
Whole femurs were dissected free of surrounding tissue. Bone marrow was flushed via needle and syringe, using 0.5 ml PBS per femur. Cellular components of bone marrow were isolated via centrifugation for 5 min at 2000 rpm. Pellets were resuspended in TRIzol (Invitrogen, Paisley, UK) prior to RNA extraction. Flushed femurs were also retained. A 0.4-cm section of the femoral midshaft was obtained to minimize contamination by muscle and cartilage adhering to femoral epiphyses and standardize anatomical localization. Material from two to six femoral cortices was pooled in RNAlater (Ambion, Huntingdon, Cambs., UK). Where tissue from more than one animal was used, material from litter mates was pooled. Femoral midshaft samples were later transferred into TRIzol (Invitrogen) and immediately homogenized using a Yellowline DI18 basic electronic homogenizer (Yellowline; IKA, Staufen, Germany) prior to RNA extraction via the manufacturer's protocol. RNA samples were quantitated using formaldehyde gel electrophoresis and spectrophotometry (Camspec, Sawston, Cambs., UK). Different pooled RNA samples were used for labeling array repetitions. Total RNA (10 µg) was labeled with either Cy3 or Cy5 dyes using the CyScribe labeling system (GE Healthcare, Chalfont St. Giles, Bucks., UK), according to the manufacturer's protocol. Labeled cDNA (1 µl) was combined with 2 µl 50% glycerol, run on a "John gel" (a microscope slide-sized, 1.5% agarose gel) and scanned using a GeneTac LS IV scanner (Genomic Solutions, Huntingdon, Cambs., UK) to assess successful incorporation of label. Control and experimental samples were then combined and prepared for hybridization.

Arrays: hybridization, image, and data analysis.
Microarray analysis was performed using the mouse National Institute on Aging (NIA) 15000 set from the Human Genome Mapping Project (HGMP), as described at the following website: http://www.ncbi.nlm.nih.gov/geo/ (platform accession no. GPL 5458). The following comparisons were carried out: 1) 17-wk 129SvEv Sparc^tm1cam null, male vs. 17-wk129Sv/Ev wild-type male, bone marrow; 2) 17-wk 129SvEv Sparc^tm1cam null, male vs. 17-wk 129Sv/Ev wild-type, male, femoral midshaft; 3) 40-wk 129SvEv Sparc^tm1cam null, male vs. 40-wk 129Sv/Ev wild-type, male, bone marrow; 4) 40-wk 129SvEv Sparc^tm1cam null, male vs. 40-wk 129Sv/Ev wild-type, male, femoral midshaft.

Hybridization and scanning were carried out as previously described (17). Arrays were repeated five times with fluor switching, to counteract any issues of dye bias that may have arisen from direct labeling. As the arrays contained duplicate spots, this allowed analysis of 10 spots per EST. Repetitions were derived from different RNA samples, to control for biological variation. Scanned images were stored and filtered and then analyzed using the GeneTac Analyser spot finding software (Genomic Solutions, Huntingdon, Cambs., UK). Data were analyzed as previously described (28), but, in brief, ESTs that were deemed to be significantly differentially regulated were changed in expression levels by at least twofold in 8 out of 10 replicates, were above background plus 2 SD in at least one channel and showed a delta value of at least 0.5 using Significance Analysis of Microarrays software (http://www-stat.stanford.edu/tibs/SAM). These ESTs were subjected to bioinformatic analysis and were assessed via semiquantitative RT-PCR to confirm array results. Data presented here are in full compliance with MIAME standards (8). Data are available from the GEO database, under series number GSE8381. We have also exceeded the requirements of MIAME in PCR testing every potentially differentially regulated gene. We also analyzed the femur dataset from the control animals to identify genes highly expressed in normal bone. ESTs that were expressed above background + 2 SD in all five array repetitions, in both 4-mo and 9-mo animals were selected. These were analyzed using DAVID (http://niaid.abcc.ncifcrf.gov/). Gene details were later checked and amended where necessary, with reference to the National Center for Biotechnology Information (NCBI) website (http://www.ncbi.nlm.nih.gov). Gene details are presented in Supplementary Table S1.¹

RT-PCR array confirmations.
We tested all genes arising from the four experiments using semiquantitative RT-PCR. RNAs were quantified as described above. Even quantities of control and experimental RNA (usually 2–4 µg) were treated with DNA free (Ambion) according to the manufacturer's protocol. Reverse transcription (RT) reactions were carried out using the Superscript II First Strand Synthesis System for RT-PCR (Invitrogen), according to the manufacturer's instructions. A "no RT" control corresponding to each sample was also produced; these were treated in exactly the same way as the samples except that Superscript II reverse transcriptase (Invitrogen) was not added. Standard primers were used for housekeeping genes; β-actin, β-microglobulin, and GAPDH (see Table 1 for primer sequences). We used three housekeeping genes in conjunction to ensure that biased expression of one would not adversely affect results. Moreover, the three housekeeping genes used were present on the NIA arrays and were not significantly altered in expression. Primers for ESTs were designed as previously described (28) (see also Table 1). PCRs were initially carried out at the optimum melting temperature indicated, including No RT controls. Conditions were varied in order that only single bands appeared and the number of cycles for minimum visibility on a gel was always identified. We ensured that PCR bands obtained for housekeeping controls were even at minimum visibility cycles before testing other genes. To minimize false positive results, we used at least two sets of Sparc null and two sets of control cDNAs from different animals. Variation was observed in both sets in order for a gene to be confirmed as variably expressed. PCRs were carried out in 20-µl volumes using 0.025-µmol concentrations of each dNTP (100 mM dNTP set, Invitrogen) and 1 unit Taq DNA polymerase (Sigma) per reaction. PCRs were usually carried out using PCR buffer (Sigma) containing 15 mM MgCl₂; however, we varied magnesium concentrations where necessary to optimize results. Annealing temperature and the number of cycles were varied, up to a maximum of 50 cycles; finally, some primers were also redesigned. Final PCR conditions are indicated for confirmed genes in Fig. 4. PCR changes were quantified from .tif files using Scion Image (Scion), via the Scion Image protocol for analyzing electrophoretic gels. PCR intensity changes (Fig. 4) were calculated via the following equation:

Changes <1 were converted to fold changes as follows: –1/X.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES

View larger version (11K): [in this window] [in a new window]   Fig. 1. Development of body weight, bone marrow adiposity, and circulating leptin concentrations in control () and 129SvEv Sparctm1cam null mice. Parameters shown are body weight (A), bone marrow adipocyte number (B), bone marrow adipocyte size (C), % area occupied by adipocytes (D), and plasma leptin concentrations (E). Values shown are means ± SD (n = 6–9; *, **, and ***P < 0.05, 0.01, and 0.001, respectively, vs. control of the same age; +, ++, and +++P < 0.05, 0.01, and 0.001, respectively, vs. same animal at different age).

Femoral length and morphology.
In 129SvEv mice femoral length increased by 4% between 4 and 9 mo (P < 0.01, Fig. 2A). Over the same period, there was no significant increase in femoral length in 129SvEv Sparc^tm1cam mice, femoral length becoming 4% shorter by 9 mo (P < 0.001, Fig. 2A). Measurement of middiaphyseal femoral diameters revealed that in 129SvEv mice neither medio-lateral, nor anterior-posterior diameters changed over the same period (Fig. 2, B and C). However, in 129SvEv Sparc^tm1cam mice, medio-lateral diameter increased by 10% over this age range (P < 0.01, Fig. 2B), whilst anterior-posterior diameter remained unaltered. At no point were either measures of diameter different between 129SvEv Sparc^tm1cam mice and their wild-type counterparts.

View larger version (10K): [in this window] [in a new window]   Fig. 2. Development of femoral geometry and mineral content in control () and 129SvEv Sparctm1cam null mice (•). Parameters shown are femoral length (A), middiaphyseal medio-lateral (M/L) diameter (B), middiaphyseal anterior-posterior (A/P) diameter (C), areal bone mineral density (aBMD, D), bone mineral content (BMC, E). Values shown are means ± SD (n = 10–16 for A, B, and C, and 6–13 for D and E; *, **, and ***P < 0.05, 0.01, and 0.001, respectively, vs. control of the same age; +, ++, and +++P < 0.05, 0.01, and 0.001, respectively, vs. same animal at different age).

Femoral strength.
Strength testing of middiaphyseal femora revealed that failure load did not increase significantly between 4 and 9 mo in 129SvEv mice (Fig. 3A). Despite a similar femoral strength at 4 mo, failure load in 129SvEv Sparc^tm1cam mice diverged from that in their wild-type counterparts, becoming 20% lower at 9 mo of age (P < 0.01, Fig. 3A). The absence of any significant age- or strain-related differences in the second moment of area revealed that there was no significant contribution of geometric variables to the recorded differences in femoral strength (Fig. 3B). Although in 129SvEv Sparc^tm1cam mice the mean UTS at 9 mo was only 78% of that in 4-mo-old 129SvEv Sparc^tm1cam mice, none of the means were significantly different (Fig. 3B).

View larger version (6K): [in this window] [in a new window]   Fig. 3. Development of femoral strength in control () and 129SvEv Sparctm1cam null mice (•). Parameters shown are failure load (A), second moment of area (B), and ultimate tensile stress (C). Values shown are means ± SD (n = 13–16; **P < 0.01 vs. control of the same age).

Bone marrow.
Analysis of bone marrow samples at both 4 and 9 mo showed no statistically significant differences between 129SvEv Sparc^tm1cam null mice and 129SvEv controls. When we looked at Sparc expression in controls, it was often so low that values were beneath background + 2 SD, thereby eliminating Sparc from further analysis. If Sparc is not highly expressed in a majority of marrow cells, the effect of knocking it out in this tissue may be minimal. Another possibility is that, owing to high heterogeneity of cell type within the bone marrow, significant expression differences between cell subtypes may be difficult to detect.

Femoral midshaft.
Analysis of femoral midshaft bone arrays showed that five genes (including Sparc) were differentially regulated at 4 mo between 129SvEv Sparc^tm1cam null mice and 129SvEv controls, while 15 genes (also including Sparc) were differentially regulated at the 9-mo time point (see Table 1). The presence of the Sparc gene acted as a good internal control and was reliably detected in each of the femur datasets as downregulated.

Via semiquantitative RT-PCR, we were able to confirm the downregulation of Sparc at 4 and 9 mo and of five other genes, zinc finger protein 162 (Zfp162), Bystin-like 1 (Bysl), transcription factor E2F4, and two uncharacterized ESTs, BG066811 and BG065585, at 9 mo (Fig. 4). Bioinformatic analysis of these genes is presented in Table 2. We also analyzed the femur dataset from the control animals to identify genes highly expressed in normal bone. Details of 429 highly expressed ESTs are presented in Supplementary Table S1. Some of these represent the same gene; having taken redundancies into account, we find there are a total of 403 entries. Of these, 204 genes are mapped to UniGene clusters, some of which are well characterized functionally; 16 map to the mouse mitochondrion; and 183 are completely uncharacterized as of 23rd February, 2007. We have compared the composition of our dataset with other array studies previously presented. Microarray datasets involving biglycan-deficient preosteoblasts, glucocorticoid-treated osteoblasts, and early osteoblast differentiation did not contain any of the genes we noted above (12, 14, 26). However, all of these studies involved cultured osteoblasts as opposed to live bone samples. Similarly, we have compared the chromosomal locations of our genes with a quantitative trait locus (QTL) mapping study using 129S1/SvImJ mice (the only mapping study we could find where strain 129 mice were used to map bone density) (24). None of the locations of our genes matched to QTLs identified; however, we have included mouse and human chromosomal locations in Table 2 for ease of comparison with other such studies.

View larger version (18K): [in this window] [in a new window]   Fig. 4. RT-PCR confirmation of genes differentially regulated in 4- and 9-mo 129SvEv Sparctm1cam null mice. Gene name, number of PCR cycles, and annealing temperature used are given to the right. Lane labels identify the following: C = control, 129SvEv bone; Sp = 129SvEv Sparctm1cam null bone; NC and NSp indicate the corresponding No RT controls. Two sets of samples from different control and experimental animals were used. β-Actin, β-globulin, and Gapdh are housekeeping controls. Residual Sparc expression is often detected by PCR in knockouts, but Western blots have confirmed the absence of functional protein (19).

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES

Our Sparc null mutation is present in a genetic background that normally specifies high bone density (3, 4); as a result we have a milder phenotype than that previously reported (15). Differences in BMC and aBMD were noted at both 4- and 9-mo time points, but mechanical strength only differed significantly at 9 mo. This impairment of strength appears to be accounted for by a change in material properties rather than a change in the size of the bones. We also noted a small but significant reduction (3–4%) in femoral length in 129SvEv Sparc^tm1cam null mice. Length is inversely related to strength, but the potential of this variable is largely negated in our study via the use of a fixed span in the three-point bending protocol. Previous reports had indicated no change in skeletal size (2, 19). However, Sparc^tm1cam null mice were studied initially on a Mf1^bb/129Sv/Ev outbred mixed background. Preliminary observations using these mice and Mf1bb controls showed such high degrees of individual variability in most skeletal parameters (unpublished data), which we subsequently used inbred 129SvEv mice. Given the small difference observed, it is also likely that this would be undetectable even on a "fixed" mixed background derived from two inbred lines (such as that studied in the exon 4 knockout).

Previous reports note increased adiposity in exon 4 Sparc null mice (7); conversely, Sparc expression is increased in three different mouse models of obesity and altered in human obesity cases (36). These results point to a complex role for Sparc in adipose regulation. We therefore assessed body weight and adiposity in these animals. Adipocytes, osteoblasts, and cartilage originate from the same lineage, mesenchymal stem cells (6, 7, 20), therefore absence of Sparc may perturb mesenchymal differentiation at the expense of the osteoblast lineage. Skeletal size differences are minor and only appear in later life, indicating that an effect on cartilage differentiation and skeletal patterning is unlikely, but marrow stroma from 129SvC57BL/6 Sparc null mice contains fewer osteoblasts and shows an increased tendency to form adipocytes (16), suggesting preferential adipocytic differentiation at the expense of the osteoblast lineage. To address these issues, we have assessed the size and number of bone marrow adipocytes. These studies, involving staining and counting of adipocytes in fixed tibial sections, are advantageous in that this method rules out any effect of cell culture on cell numbers and may be more indicative of any perturbations in stem cell differentiation than analysis of peripheral fat depots. The numbers of marrow adipocytes do not vary significantly (although their volume does at one time point), indicating that the lack of Sparc has more effect on lipid accumulation than on differentiation or proliferation. However, adipocytes in marrow are thought to secrete leptin; larger adipocytes secreting proportionately more. It is conceivable that marrow-derived leptin may exert a paracrine influence on bone formation without changing levels of circulating leptin.

Exon 4 129SvC57BL/6 Sparc null mice have been shown to have larger deposits of subcutaneous and epididymal fat and to display raised serum leptin levels between 6–8 mo (7). In contrast, we failed to note a difference in circulating leptin concentration at 9 mo, but noted a significant decrease in leptin concentrations at 17 wk. We also noticed a substantial increase in body weight at 17 wk [a time point not tested in the prior study (7)], which had disappeared at 40 wk (9 mo). These differences are probably not diet related, as food fat contents were similar [4.3% fat, our study vs. 4% fat, previous study (7)]. Mirroring the raised 17-wk body weight, we noted significant increases in the size of marrow adipocytes and the percentage of the marrow cavity occupied by adipocytes at the same time point. No increase in marrow adipocyte number was noted, differing from subcutaneous and epididymal fat in 129Sv/C57BL/6 Sparc null mice, in which both adipocyte number and size were increased. Although peripheral and marrow fat deposits may be regulated in a differential manner, our results would concur with previous reports that absence of Sparc appears to cause abnormalities of adipose metabolism. Genetic aspects of adipose biology differ between inbred strains of mice and may lead to variations in adipose response to the lack of Sparc.

Since we have confirmed that 129SvEv Sparc^tm1cam null mice show an impaired skeletal phenotype, these mice are therefore an ideal model with which to carry out array studies in bone; experimental and control lines used in this study should be genetically identical apart from the Sparc null mutation, removing a common source of noise. Sparc was downregulated at 4 and 9 mo; the presence of Sparc within the NIA set acts as an internal control and confirms array validity. Aside from Sparc, we have identified five downregulated genes in 9-mo 129SvEv Sparc^tm1cam null mice. This mirrors previous findings in the lens, where we were unable to detect differential regulation of anything other than Sparc at 4 mo, whereas a large number of genes were differentially regulated at 9 mo (28). As we have found in bone, the majority of differentially regulated genes in early stage cataract were also downregulated (a result also noted by others investigating cataract via array) (28, 33).

These results imply that the absence of Sparc does not immediately result in the dysregulation of other genes. Repetition of this result in bone was somewhat surprising though, as, in the genetic backgrounds we used, Sparc^tm1cam lenses are asymptomatic at 4 mo; overt cataract has yet to develop. In contrast, 129SvEv Sparc^tm1cam bone is already compromised at this stage. Possibly the initial cause of bone weakness (and cataract) in Sparc null mice is simply its absence; this may then be followed by progressive alterations in gene expression as the phenotype develops over time. Other than Sparc itself, we have not noted any genes that are differentially regulated in both lens and bone datasets. This implies that Sparc is not having a major effect on signaling pathways common to both lens and bone (tissues that remodel constantly throughout life). There are a number of genes that have a high homology to Sparc [hevin/Sc1, Spock 1-3 (also known as testicans 1-3), Smoc1, and Smoc2]. Our arrays have not detected differential regulation of any of these to compensate for the absence of Sparc. It should be noted however, that the NIA set contains only 15,000 ESTs, in which there is a degree of redundancy (28). This hypothesis has not been tested on an array dataset that is representative of the entire mouse genome.

The nature of the differentially regulated genes is interesting. The Unigene clusters representing three of these genes, E2F4, Bysl, and Zfp162, quote bone and sometimes bone marrow as a tissue source, demonstrating their relevance to bone biology. E2F4 knockout mice have been generated; erythroid abnormalities during development and craniofacial abnormalities have been noted (22). Of further relevance is the fact that this gene regulates adipocyte differentiation. Zfp 162 and Bysl are less well investigated; however, high levels of expression in macrophages (which are bone marrow derived and which fuse in some cases to form osteoclasts) have been noted for Zfp 162 (10). The remaining two genes are functionally uncharacterized. Notably, despite the number of ESTs present on the array, we have not seen relative changes in biomarkers for bone metabolism, in either bone or in bone marrow, which contains both osteoblast and osteoblast precursors.

Using data from control animals, we have also identified 403 genes that are highly expressed in bone. Of these, 183 are completely uncharacterized. These data may be a useful resource in identifying novel candidate genes for skeletal disease, especially as a large number of linkage and association studies have delineated wide intervals in which important genes reside, but, owing to the number of genes within the critical regions, many have not yet been identified (21).

Despite the wealth of data from various genome and EST projects (23, 25), biochemical pathways identified in bone are still incomplete, while large proportions of genes or ESTs identified by large scale sequencing projects are relatively functionally uncharacterized, implying that many vital regulators of skeletal homeostasis remain to be elucidated. The use of microarrays in combination with knockout mice explores phenotype in a complex world of development, ageing, and environment and can also be used to elucidate currently unidentified components of essential biological processes such as skeletal metabolism. Identification of genes dysregulated during abnormal bone thinning may lead us to novel routes of therapeutic intervention for osteoporosis. This topic is also important in that it will allow us to develop our knowledge of the biology and biochemical mode of action of Sparc, which we have confirmed as an potentially important therapeutic target for osteoporosis.

In summary, our data predicate the utility of 129SvEv Sparc^tm1cam null mice as a model of low turnover osteopenia. We have also identified a number of genes that may contribute to the impairment of bone in the absence of Sparc.

	GRANTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES

 
This work was funded by the Wellcome Trust and the Biotechnology and Biological Sciences Research Council.

	ACKNOWLEDGMENTS

 
We thank The HGMP Centre for provision of the NIA microarray slides used in this study. We also thank Anna Hurley and Steve Turner, Vicky Workman, and Steffan Adams at the Cardiff University Array facility for assistance with array protocols, scanning, image analysis, data storage, and bioinformatics.

S. L. Evans, M. J. Evans, and B. A. J. Evans are members of CITER (Cardiff Institute of Tissue Engineering and Repair).

Databases used: NCBI site, http://www.ncbi.nlm.nih.gov; UniGene, http://www.ncbi.nlm.nih.gov/UniGene; DAVID, http://niaid.abcc.ncifcrf.gov/ and GEO, http://www.ncbi.nlm.nih.gov/geo/.

Present address for F. C. Mansergh: Ocular Genetics Unit, Smurfit Inst. of Genetics, Univ. of Dublin, Trinity College, Ireland (e-mail: manseighf{at}tcd.ie).

	FOOTNOTES

 
Address for reprint requests and other correspondence: F. C. Mansergh, Ocular Genetics Unit, Smurfit Inst. of Genetics, Univ. of Dublin, Trinity College; Ireland (e-mail: manserghf{at}tcd.ie).

Article published online before print. See web site for date of publication (http://physiolgenomics.physiology.org).

¹ The online version of this article contains supplemental material.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES

 

1. Baldock PA, Eisman JA. Genetic determinants of bone mass. Curr Opin Rheumatol 16: 450–445, 2004.[CrossRef][Web of Science][Medline]
2. Bassuk JA, Birkebak T, Rothmier JD, Clark JM, Bradshaw A, Muchowski PJ, Howe CC, Clark JI, Sage EH. Disruption of the Sparc locus in mice alters the differentiation of lenticular epithelial cells, and leads to cataract formation. Exp Eye Res 68: 321–331, 1999.[CrossRef][Web of Science][Medline]
3. Beamer WG, Donahue LR, Rosen CJ, Baylink DJ. Genetic variability in adult bone density among inbred strains of mice. Bone 18: 397–403, 1996.[Medline]
4. Beamer WG, Shultz KL, Donahue LR, Churchill GA, Sen S, Wergedal JR, Baylink DJ, Rosen CJ. Quantitative trait loci for femoral, and lumbar vertebral bone mineral density in C.57BL/6J and C3H/HeJ inbred strains of mice. J Bone Miner Res 16: 1195–1206, 2001.[CrossRef][Web of Science][Medline]
5. Boskey AL, Moore DJ, Amling M, Canalis E, Delany AM. Infrared analysis of the mineral, and matrix in bones of osteonectin-null mice and their wildtype controls. J Bone Miner Res 18: 1005–1011, 2003.[CrossRef][Web of Science][Medline]
6. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation, and tissue response to injury. J Clin Invest 107: 1049–1054, 2001.[Web of Science][Medline]
7. Bradshaw AD, Graves DC, Motamed K, Sage EH. SPARCnull mice exhibit increased adiposity without significant differences in overall body weight. Proc Natl Acad Sci USA 100: 6045–6050, 2003.[Abstract/Free Full Text]
8. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29: 365–371, 2001.[CrossRef][Web of Science][Medline]
9. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol 19: 569–580, 2001.[CrossRef][Web of Science]
10. Caslini C, Spinelli O, Cazzaniga G, Golay J, De Gioia L, Pedretti A, Breviario F, Amaru R, Barbui T, Biondi A, Introna M, Rambaldi A. Identification of two novel isoforms of the ZNF162 gene: a growing family of signal transduction and activator of RNA proteins. Genomics 42: 268–277, 1997.[CrossRef][Web of Science][Medline]
11. Chavey C, Boucher J, Monthouel-Kartmann MN, Sage EH, Castan-Laurell I, Valet P, Tartare-Deckert S, Van Obberghen E. Regulation of secreted protein acidic and rich in cysteine during adipose conversion and adipose tissue hyperplasia. Obesity 14: 1890–1897, 2006.[Web of Science][Medline]
12. Chen XD, Bian X, Teslovich TM, Stephan DA, Young MF. Dissection of the sets of genes that control the behavior of biglycan-deficient pre-osteoblasts using oligonucleotide microarrays. Bone 37: 192–203, 2005.[Medline]
13. Crusio WE. Flanking gene and genetic background problems in genetically manipulated mice. Biol Psychiatry 56: 381–385, 2004.[CrossRef][Web of Science][Medline]
14. DeJong DS, Vaes BL, Dechering KJ, Feijen A, Hendriks JM, Wehrens R, Mummery CL, van Zoelen EJ, Olijve W, Steegenga WT. Identification of novel regulators associated with early-phase osteoblast differentiation. J Bone Miner Res 19: 947–958, 2004.[CrossRef][Web of Science][Medline]
15. Delany AM, Amling M, Priemel M, Howe C, Baron R, Canalis E. Osteopenia and decreased bone formation in osteonectin-deficient mice. J Clin Invest 105: 1325, 2000.[Web of Science][Medline]
16. Delany AM, Kalajzic I, Bradshaw AD, Sage EH, Canalis E. Osteonectin-null mutation compromises osteoblast formation, maturation, and survival. Endocrinology1 44: 2588–2596. 2003.
17. Ferrari SL, Rizzoli R. Gene variants for osteoporosis and their pleiotropic effects in aging. Mol Aspects Med 26: 145–167, 2005.[CrossRef][Medline]
18. Gevers EF, Loveridge N, Robinson IC. Bone marrow adipocytes: a neglected target tissue for growth hormone. Endocrinology 143: 4065–4073, 2002.[Abstract/Free Full Text]
19. Gilmour DT, Lyon GJ, Carlton MB, Sanes JR, Cunningham JM, Anderson JR, Hogan BL, Evans MJ, Colledge WH. Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens. EMBO J 17: 1860–1870, 1998.[CrossRef][Web of Science][Medline]
20. Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev 78: 783–809, 1998.[Abstract/Free Full Text]
21. Huang QY, Kung AWC. Genetics of osteoporosis. Mol Genet Metab 88: 295–306, 2006.[CrossRef][Web of Science][Medline]
22. Humbert PO, Rogers C, Ganiatsas S, Landsberg RL, Trimarchi JM, Dandapani S, Brugnara C, Erdman S, Schrenzel M, Bronson RT, Lees JA. E2F4 is essential for normal erythrocyte maturation and neonatal viability. Mol Cell 6: 281–291, 2000.[CrossRef][Web of Science][Medline]
23. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409: 860–921, 2001.[CrossRef][Medline]
24. Ishimori N, Li R, Walsh KA, Korstanje R, Rollins JA, Petkov P, Pletcher MT, Wiltshire T, Donahue LR, Rosen CJ, Beamer WG, Churchill GA, Paigen B. Quantitative Trait Loci That Determine BMD in C57BL/6J and 129S1/SvImJ Inbred Mice. J Bone Miner Res 21: 105–112, 2006.[CrossRef][Web of Science][Medline]
25. Kawai J, Shinagawa A, Shibata K, Yoshino M, Itoh M, Ishii Y, Arakawa T, Hara A, RIKEN Genome Exploration Research Group. Phase II Team and the FANTOM Consortium Functional annotation of a full-length mouse cDNA collection. Nature 409: 685–90, 2001.[CrossRef][Medline]
26. Leclerc N, Luppen CA, Ho VV, Nagpal S, Hacia JG, Smith E, Frenkel B. Gene expression profiling of glucocorticoid-inhibited osteoblasts. J Mol Endocrinol 33: 175–193, 2004.[Abstract]
27. Long MW. Osteogenesis and bone-marrow-derived cells. Blood Cells Mol Dis 27: 677–690, 2001.[CrossRef][Web of Science][Medline]
28. Mansergh FC, Wride MA, Walker VE, Adams S, Hunter SM, Evans MJ. Gene expression changes during cataract progression in Sparc null mice: differential regulation of mouse globins in the lens. Mol Vis 10: 490–511, 2004.[Web of Science][Medline]
29. Mason IJ, Murphy D, Munke M, Francke U, Elliott RW, Hogan BLM. Development and transformation sensitive expression of the Sparc gene on mouse chromosome 11. EMBO J 5: 1465–1472, 1986.[Web of Science][Medline]
30. McLean W, Olsen BR. Mouse models of abnormal skeletal development and homeostasis. Trends Genet 17: S38–S43, 2001.[CrossRef][Medline]
31. Norose K, Clark JI, Syed NA, Basu A, Heber-Katz E, Sage EH, Howe CC. SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis Sci 39: 2674–2680, 1998.[Abstract/Free Full Text]
32. Ralston SH, deCrombrugghe B. Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev 20: 2492–2506, 2006.[Abstract/Free Full Text]
33. Ruotolo R, Grassi F, Percudani R, Rivetti C, Martorana D, Maraini G, Ottonello S. Gene expression profiling in human age-related nuclear cataract. Mol Vis 9: 538–548, 2003.[Web of Science][Medline]
34. Samuels A, Perry MJ, Gibson RL, Colley S, Tobias JH. Role of endothelial nitric oxide synthase in estrogen-induced osteogenesis. Bone 29: 24–29, 2001.[Medline]
35. Takeshita S, Namba N, Zhao JJ, Jiang Y, Genant HK, Silva MJ, Brodt MD, Helgason CD, Kalesnikoff J, Rauh MJ, Humphries RK, Krystal G, Teitelbaum SL, Ross FP. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med 8: 943–949, 2002.[CrossRef][Web of Science][Medline]
36. Tartare-Deckert S, Chavey C, Monthouel MN, Gautier N, Van Obberghen E. The matricellular protein SPARC/osteonectin as a newly identified factor up-regulated in obesity. J Biol Chem 276: 22231–22237, 2001.[Abstract/Free Full Text]
37. Teitelbaum SL. Bone resorption by osteoclasts. Science 289: 1504–1508, 2000.[Abstract/Free Full Text]
38. Watanabe K, Hishiya A. Mouse models of senile osteoporosis. Mol Aspects Med 26: 221–231, 2005.[CrossRef][Medline]

This article has been cited by other articles:

				D. Del Prete, B. Polverino, M. Ceol, D. Vianello, F. Mezzabotta, E. Tiralongo, M. Iafrate, E. De Canale, C. Mengoli, M. Valente, et al. Encrusted cystitis by Corynebacterium urealyticum: a case report with novel insights into bladder lesions Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2685 - 2687. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Supplemental Table All Versions of this Article: 32/1/64    most recent 00151.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Mansergh, F. C. Articles by Evans, B. A. J. Search for Related Content PubMed PubMed Citation Articles by Mansergh, F. C. Articles by Evans, B. A. J.